Editas Medicine (EDIT) Short Interest Ratio & Short Volume → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free EDIT Stock Alerts $5.62 0.00 (0.00%) (As of 11:16 AM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Editas Medicine Short Interest DataCurrent Short Interest20,500,000 sharesPrevious Short Interest18,760,000 sharesChange Vs. Previous Month+9.28%Dollar Volume Sold Short$106.81 millionShort Interest Ratio10.3 Days to CoverLast Record DateApril 30, 2024Outstanding Shares82,240,000 sharesPercentage of Shares Shorted24.93%Today's Trading Volume272,780 sharesAverage Trading Volume1,826,787 sharesToday's Volume Vs. Average15% Short Selling Editas Medicine ? Sign up to receive the latest short interest report for Editas Medicine and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartEDIT Short Interest Over TimeEDIT Days to Cover Over TimeEDIT Percentage of Float Shorted Over Time Ad Stansberry ResearchEverybody laughed when he recommended Netflix"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. Editas Medicine Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202420,500,000 shares $106.81 million +9.3%N/A10.3 $5.21 4/15/202418,760,000 shares $114.06 million +14.7%N/A9.8 $6.08 3/31/202416,360,000 shares $121.39 million +17.4%N/A8.9 $7.42 3/15/202413,930,000 shares $113.25 million +3.0%N/A7.5 $8.13 2/29/202413,520,000 shares $136.01 million +7.4%N/A7 $10.06 2/15/202412,590,000 shares $104.62 million +3.1%N/A7.2 $8.31 Get the Latest News and Ratings for EDIT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. 1/31/202412,210,000 shares $85.84 million -2.2%N/A6.7 $7.03 1/15/202412,480,000 shares $113.19 million -2.4%N/A6.8 $9.07 12/31/202312,790,000 shares $129.56 million -14.6%N/A7 $10.13 12/15/202314,970,000 shares $163.62 million -5.1%N/A7.7 $10.93 11/30/202315,780,000 shares $166.16 million -0.6%N/A8.9 $10.53 11/15/202315,870,000 shares $140.29 million -5.4%N/A9.7 $8.84 10/31/202316,770,000 shares $112.02 million +2.1%N/A11 $6.68 10/15/202316,420,000 shares $115.76 million +2.8%N/A11.2 $7.05 9/30/202315,970,000 shares $124.57 million +5.2%N/A11.1 $7.80 9/15/202315,180,000 shares $127.36 million +4.7%N/A10.8 $8.39 8/31/202314,500,000 shares $129.20 million +0.6%N/A8.1 $8.91 8/15/202314,410,000 shares $126.23 million -6.7%N/A7.5 $8.76 7/31/202315,440,000 shares $135.56 million -0.2%N/A7.5 $8.78 7/15/202315,470,000 shares $133.20 million -20.4%N/A7.4 $8.61 6/30/202319,430,000 shares $159.91 million -5.8%N/A8.6 $8.23 6/15/202320,630,000 shares $191.45 million +0.6%N/A9 $9.28 5/31/202320,500,000 shares $188.19 million +1.3%N/A11 $9.18 5/15/202320,230,000 shares $202.50 million +7.3%N/A11 $10.01 4/30/202318,860,000 shares $153.90 million -5.5%N/A10.7 $8.16 4/15/202319,950,000 shares $151.42 million +1.5%N/A11.1 $7.59 3/31/202319,650,000 shares $142.46 million -4.8%N/A11.3 $7.25 3/15/202320,640,000 shares $174.00 million +7.7%N/A11.9 $8.43 2/28/202319,160,000 shares $173.21 million -2.6%N/A10 $9.04 2/15/202319,670,000 shares $203.78 million -6.1%N/A10.2 $10.36 1/31/202320,940,000 shares $207.10 million -5.4%N/A10.5 $9.89 1/15/202322,140,000 shares $186.64 million +2.3%N/A11.8 $8.43 12/30/202221,650,000 shares $192.04 million +2.3%N/A12 $8.87 12/15/202221,170,000 shares $211.91 million +7.7%N/A12.3 $10.01 11/30/202219,650,000 shares $208.29 million +4.0%N/A11.7 $10.60 11/15/202218,900,000 shares $246.65 million +2.3%N/A12.1 $13.05 10/31/202218,470,000 shares $231.80 million -0.4%N/A12.1 $12.55 10/15/202218,540,000 shares $210.99 million +2.2%N/A11.8 $11.38 9/30/202218,150,000 shares $222.16 million +5.3%N/A11 $12.24 9/15/202217,240,000 shares $277.74 million +3.4%N/A10.1 $16.11Warren Buffett's "mystery stock" (Ad)WARNING: Read This Before the Next Fed Meeting Investors are looking to the Fed with high hopes for interest rate relief. Unfortunately, many have no idea there's another major story unfolding right now, one that could be worth $40 trillion. This Wall Street millionaire just stepped forward with all the details, and how it could make some 8/31/202216,680,000 shares $245.20 million +2.7%N/A9.6 $14.70 8/15/202216,250,000 shares $299.98 million -3.1%N/A9.3 $18.46 7/31/202216,770,000 shares $266.81 million +2.4%N/A9.5 $15.91 7/15/202216,380,000 shares $245.54 million +7.0%N/A9.3 $14.99 6/30/202215,310,000 shares $181.12 million +4.7%N/A9 $11.83 6/15/202214,620,000 shares $153.95 million +1.3%N/A8.8 $10.53 5/31/202214,430,000 shares $164.36 million +10.2%N/A9.1 $11.39 5/15/202213,090,000 shares $155.38 million +3.7%N/A7.7 $11.87 4/30/202212,620,000 shares $167.09 million +0.9%N/A7.3 $13.24 4/15/202212,510,000 shares $208.54 million +1.8%N/A6.9 $16.67 3/31/202212,290,000 shares $233.76 million +4.0%N/A6.5 $19.02 3/15/202211,820,000 shares $176.24 million +3.2%N/A6.3 $14.91 2/28/202211,450,000 shares $196.02 million +3.1%N/A6.1 $17.12 2/15/202211,110,000 shares $184.98 million +1.3%N/A6.1 $16.65 1/31/202210,970,000 shares $208.87 million -3.2%N/A6.5 $19.04 1/15/202211,330,000 shares $250.39 million -0.6%N/A7.8 $22.10 12/31/202111,400,000 shares $302.67 million +5.3%N/A8.8 $26.55 12/15/202110,830,000 shares $324.25 million +9.7%N/A6.9 $29.94 11/30/20219,870,000 shares $322.35 million +3.5%N/A6.7 $32.66 11/15/20219,540,000 shares $343.34 million -4.3%N/A6.4 $35.99 10/29/20219,970,000 shares $366.10 million -1.9%N/A6 $36.72 10/15/202110,160,000 shares $386.28 million +47.3%N/A5.8 $38.02 9/30/20216,900,000 shares $283.45 million -1.4%N/A3.9 $41.08 9/15/20217,000,000 shares $422.10 million +3.4%N/A3.5 $60.30 8/31/20216,770,000 shares $430.50 million -9.7%N/A3.5 $63.59 8/13/20217,500,000 shares $469.95 million -11.7%N/A4 $62.66 7/30/20218,490,000 shares $355.39 million +1.9%N/A4.7 $41.86 7/15/20218,330,000 shares $349.78 million -20.1%12.3%5 $41.99 6/30/202110,430,000 shares $590.76 million +0.6%15.4%5.9 $56.64 6/15/202110,370,000 shares $363.99 million -2.4%15.3%8 $35.10 5/28/202110,620,000 shares $360.55 million +0.9%15.7%7.9 $33.95 5/14/202110,530,000 shares $330.64 million +1.0%N/A6.2 $31.40 4/30/202110,430,000 shares $389.77 million +1.8%N/A5.3 $37.37 4/15/202110,250,000 shares $425.68 million +0.4%N/A4.7 $41.53 3/31/202110,210,000 shares $413.51 million -3.8%N/A4.1 $40.50 3/15/202110,610,000 shares $491.03 million -6.2%N/A3.7 $46.28 2/26/202111,310,000 shares $506.24 million +14.9%N/A3.5 $44.76 2/12/20219,840,000 shares $562.55 million +9.1%N/A3.3 $57.17 1/29/20219,020,000 shares $551.39 million -5.1%N/A3.4 $61.13 1/15/20219,500,000 shares $721.24 million -3.9%N/A3.9 $75.92 12/31/20209,890,000 shares $756.59 million -9.2%N/A4.8 $76.50 12/15/202010,890,000 shares $669.63 million -1.5%N/A6.4 $61.49 11/30/202011,060,000 shares $346.62 million -1.7%N/A10.2 $31.34 11/15/202011,250,000 shares $328.84 million -0.4%N/A12.9 $29.23 10/30/202011,290,000 shares $370.26 million -0.1%N/A13.6 $32.80 10/15/202011,300,000 shares $363.41 million +7.9%N/A12.7 $32.16 9/30/202010,470,000 shares $293.79 million +7.5%N/A11.9 $28.06 9/15/20209,740,000 shares $310.71 million +6.2%N/A9.7 $31.90 8/31/20209,170,000 shares $323.06 million -0.7%N/A8.5 $35.23 8/14/20209,230,000 shares $322.31 million +4.5%N/A8.5 $34.92Warren Buffett's "mystery stock" (Ad)WARNING: Read This Before the Next Fed Meeting Investors are looking to the Fed with high hopes for interest rate relief. Unfortunately, many have no idea there's another major story unfolding right now, one that could be worth $40 trillion. This Wall Street millionaire just stepped forward with all the details, and how it could make some 7/31/20208,830,000 shares $259.25 million -0.5%N/A7.7 $29.36 7/15/20208,870,000 shares $289.34 million -5.6%N/A8.2 $32.62 6/30/20209,400,000 shares $278.05 million +3.5%N/A9 $29.58 6/15/20209,080,000 shares $262.78 million +9.3%N/A9.2 $28.94 5/29/20208,310,000 shares $224.95 million +0.7%N/A8.7 $27.07 5/15/20208,250,000 shares $216.81 million +2.0%N/A8 $26.28 4/30/20208,090,000 shares $187.04 million -1.0%N/A8.2 $23.12 4/15/20208,170,000 shares $184.07 million +5.3%N/A8.7 $22.53 3/31/20207,760,000 shares $194.08 million -8.9%N/A8 $25.01 3/13/20208,515,500 shares $188.45 million +4.1%N/A7.7 $22.13 2/28/20208,180,000 shares $160.16 million -5.4%N/A9.8 $19.58 2/14/20208,650,000 shares $187.79 million -3.2%N/A9.6 $21.71 1/31/20208,940,000 shares $200.35 million -1.2%N/A9.6 $22.41 1/15/20209,050,000 shares $244.26 million +3.7%N/A10.2 $26.99 12/31/20198,730,000 shares $247.50 million +1.5%N/A10.4 $28.35 11/15/20197,830,000 shares $219.79 million +0.9%16.5%13.7 $28.07 EDIT Short Interest - Frequently Asked Questions What is Editas Medicine's current short interest? Short interest is the volume of Editas Medicine shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 20,500,000 shares of EDIT short. Learn More on Editas Medicine's current short interest. What is a good short interest ratio for Editas Medicine? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EDIT shares currently have a short interest ratio of 10.0. Learn More on Editas Medicine's short interest ratio. Which institutional investors are shorting Editas Medicine? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Editas Medicine: Walleye Trading LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Editas Medicine's short interest increasing or decreasing? Editas Medicine saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 20,500,000 shares, an increase of 9.3% from the previous total of 18,760,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Editas Medicine's short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Editas Medicine: Voyager Therapeutics, Inc. (7.74%), Fate Therapeutics, Inc. (19.45%), Taysha Gene Therapies, Inc. (9.04%), Lexeo Therapeutics, Inc. (4.34%), Ocugen, Inc. (18.61%), TScan Therapeutics, Inc. (1.03%), Allogene Therapeutics, Inc. (32.03%), Alector, Inc. (10.20%), C4 Therapeutics, Inc. (14.74%), Replimune Group, Inc. (19.05%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Editas Medicine stock? Short selling EDIT is an investing strategy that aims to generate trading profit from Editas Medicine as its price is falling. EDIT shares are trading down $0.27 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Editas Medicine? A short squeeze for Editas Medicine occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EDIT, which in turn drives the price of the stock up even further. How often is Editas Medicine's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EDIT, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Voyager Therapeutics Short Squeeze Fate Therapeutics Short Squeeze Taysha Gene Therapies Short Squeeze Lexeo Therapeutics Short Squeeze Ocugen Short Squeeze TScan Therapeutics Short Squeeze Allogene Therapeutics Short Squeeze Alector Short Squeeze C4 Therapeutics Short Squeeze Replimune Group Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EDIT) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldUrgent Nvidia WarningAltimetryDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward PressThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star